Tecovirimat for the treatment of severe Mpox in Germany

BACKGROUND: In May 2022, a multi-national mpox outbreak was reported in several non-endemic countries. The only licensed treatment for mpox in the European Union is the orally available small molecule tecovirimat, which in Orthopox viruses inhibits the function of a major envelope protein required f...

Descripción completa

Detalles Bibliográficos
Autores principales: Hermanussen, Lennart, Brehm, Thomas Theo, Wolf, Timo, Boesecke, Christoph, Schlabe, Stefan, Borgans, Frauke, Monin, Malte B., Jensen, Björn-Erik Ole, Windhaber, Stefan, Scholten, Stefan, Jordan, Sabine, Lütgehetmann, Marc, Wiesch, Julian Schulze zur, Addo, Marylyn M., Mikolajewska, Agata, Niebank, Michaela, Schmiedel, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10240449/
https://www.ncbi.nlm.nih.gov/pubmed/37273167
http://dx.doi.org/10.1007/s15010-023-02049-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10240449/
https://www.ncbi.nlm.nih.gov/pubmed/37273167
http://dx.doi.org/10.1007/s15010-023-02049-0

Ejemplares similares